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Abstract
Background: Vitamin D insufficiency has been implicated in autoimmunity. ChIP-seq experiments using immune
cell lines have shown that vitamin D receptor (VDR) binding sites are enriched near regions of the genome
associated with autoimmune diseases. We aimed to investigate VDR binding in primary CD4+ cells from healthy
volunteers.
Methods: We extracted CD4+ cells from nine healthy volunteers. Each sample underwent VDR ChIP-seq. Our results
were analyzed in relation to published ChIP-seq and RNA-seq data in the Genomic HyperBrowser. We used
MEMEChIP for de novo motif discovery. 25-Hydroxyvitamin D levels were measured using liquid chromatography–
tandem mass spectrometry and samples were divided into vitamin D sufficient (25(OH)D ≥75 nmol/L) and
insufficient/deficient (25(OH)D <75 nmol/L) groups.
Results: We found that the amount of VDR binding is correlated with the serum level of 25-hydroxyvitamin D
(r = 0.92, P= 0.0005). In vivo VDR binding sites are enriched for autoimmune disease associated loci, especially when
25-hydroxyvitamin D levels (25(OH)D) were sufficient (25(OH)D ≥75: 3.13-fold, P<0.0001; 25(OH)D <75: 2.76-fold,
P<0.0001; 25(OH)D ≥75 enrichment versus 25(OH)D <75 enrichment: P= 0.0002). VDR binding was also enriched
near genes associated specifically with T-regulatory and T-helper cells in the 25(OH)D ≥75 group. MEME ChIP did
not identify any VDR-like motifs underlying our VDR ChIP-seq peaks.
Conclusion: Our results show a direct correlation between in vivo 25-hydroxyvitamin D levels and the number of
VDR binding sites, although our sample size is relatively small. Our study further implicates VDR binding as
important in gene-environment interactions underlying the development of autoimmunity and provides a
biological rationale for 25-hydroxyvitamin D sufficiency being based at 75 nmol/L. Our results also suggest that VDR
binding in response to physiological levels of vitamin D occurs predominantly in a VDR motif-independent manner.
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Background
Vitamin D is a secosteroid produced from 7-dehydro-
cholesterol by the action of ultraviolet (UV) radiation
within the skin and is hydroxylated to its active mole-
cule 1,25-dihydroxyvitamin D (1,25D3) by the liver and
kidneys [1]. A role for vitamin D and UV radiation in
autoimmune disease was originally suggested by the lati-
tudinal gradient in the prevalence and incidence for
many autoimmune disorders [2]. Epidemiological studies
have since confirmed the association of low levels of
vitamin D with increased susceptibility to autoimmune
disease, in some cases when vitamin D levels are mea-
sured prior to the clinical onset of disease [3-6]. The
ideal dose of vitamin D supplementation to achieve a
sufficient level of 25-hydroxyvitamin D is not clear, al-
though it appears to be in excess of 800 international
units [7].
1,25D3 acts intracellularly via the vitamin D receptor
(VDR), a nuclear receptor that forms dimers with retin-
oid X receptors (RXR) to bind DNA and alter gene tran-
scription [8]. Two studies have analyzed genome-wide
binding of VDR using chromatin immunoprecipitation
with massively parallel sequencing (ChIP-seq); one using
a B-lymphoblastic cell line (LCL) and another using a
monocytic cell line (MCL) [9,10]. The methods of vita-
min D stimulation used in each study differed markedly
and this may contribute to the differences in VDR bind-
ing observed in addition to cell-specific differences [11].
Each study determined that the VDR-RXR dimer recog-
nizes a classical motif (DR3) but that this is present only
at some of the VDR binding sites detected by ChIP-seq.
The LCL ChIP-seq used genetic susceptibility loci drawn
from genome-wide association studies to demonstrate
significant overlap between autoimmune susceptibility
regions and VDR binding sites [9].
However, in vivo, the situation is likely to be very dif-
ferent, both because DNA accessibility is likely to be al-
tered in cell lines compared with primary immune cells
and also because long-term exposure to physiological
levels of 1,25D3 is not replicated well by short-term
stimulation with high levels of 1,25D3 [12-14]. In the
present study we, therefore, aimed to use ChIP-seq to
study VDR binding in primary CD4+ cells drawn from
healthy individuals with measured serum levels of 25-
hydroxyvitamin D.
Methods
Subjects
Healthy volunteers were recruited from the general pub-
lic and nine samples of whole blood obtained (1_VDR,
2_VDR, 3_VDR, 4_VDR, 5_VDR, HB, PD, SP and SR).
CD4+ lymphocytes were separated from whole blood
using magnetic-activated cell sorting (MACS) as described
in [15]. This project was approved by the Mid and
South Buckinghamshire Research Ethics Committee
(REC Reference # 09/H0607/7).
25-hydroxyvitamin D measurements
25-Hydroxyvitamin D was measured using liquid chro-
matography–tandem mass spectrometry.
ChIP-seq
This was performed as in [9]. Briefly, CD4+ cells were
fixed with 1% formaldehyde for 15 minutes then quen-
ched with 0.125 M glycerine. Lysis buffer was added to
isolate chromatin and the samples were disrupted with a
Douce homogenizer. Sonication was used to sheer the
resultant protein-DNA complex into 300 to 500 base
pair fragments (Misonix, Farmindale, NY 11735, USA).
DNA was quantified using a Nanodrop (Wilmington, DE
19810, USA) spectrophotometer.
Aliquots containing 50 μg of chromatin were pre-
cleared with protein A agarose beads (Invitrogen, Paisley
PA4 9RF, UK). Genomic regions bound by VDR were
precipitated out using anti-VDR rabbit antibody (Santa
Cruz Biotechnology, sc-1008, Dallas, Texas 75220, USA)
and isolated with protein A agarose beads. This was in-
cubated at 4°C overnight, then washed and antibody-
bound fragments eluted from the beads with SDS buffer.
Samples were treated with proteinase K and RNase.
Crosslinks were reversed by incubation overnight at
65°C. ChIP-DNA was purified by subsequent phenol-
chloroform extraction and ethanol precipitation.
The purified product was then prepared for sequen-
cing as per the Illumina ChIP-seq library generation
protocol. The resultant DNA libraries were sent to
Vanderbilt Microarray Shared Resource where they
were sequenced on a Genome Analyzer II. Sequence
reads (35 bases; 20 to 30 million quality filtered reads/
sample) were aligned to the human genome (National
Center for Biotechnology Information Build 37) using
bowtie (0.10.1, [16], options ‘-n 2 -a —best —strata -
m 1 -p 4’).
ChIP-seq peak calling and artefact filtering
VDR ChIP-seq peaks were called using Zinba (zero-in-
flated negative binomial algorithm,refine peaks, exten-
sion = 200) with the false discovery rate set as <0.1%
[17]. We removed peaks that showed overlap with re-
gions known to give false positive ChIP-seq peaks by
merging Terry’s blacklist and the list of ultra-high signal
artefact regions [18]. ChIP-seq peaks are detailed in the
(Additional file 1) dataset. We also called peaks separ-
ately using model-based analysis of ChIP-Seq (MACS)
for further motif analysis [19].
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Motif analysis
MEME-ChIP [20], Weeder [21] and ChIPmunk [22] were
used to identify de novo motifs from VDR ChIP-seq peaks
from groups of samples with 25-hydroxyvitamin D <75 nM
and ≥75 nM, intervals overlapping with LCL/MCL VDR
ChIP-seq peaks and intervals overlapping with RXR ChIP-
seq peaks from NB4 cells [20,23]. ChIP-seq peaks were
also scanned for known VDR recognition motifs using
RSAT [24] and Fimo [25].
GREAT gene ontology analysis
25(OH)D ≥75 and 25(OH)D <75 VDR binding sites were
input into the Genomic Regions Enrichment of Annota-
tions Tool (GREAT) using the GRCh37 (UCSC hg19,
February 2009) assembly and 5 kb proximal and 1 kb
distal gene windows [26].
Overlap and hierarchal clustering analysis
The Genomic HyperBrowser was used to determine
overlap and hierarchal clustering between different da-
tasets [27,28]. Autoimmune disease-associated regions
were determined as those 100 kb either side of a SNP as-
sociated with an autoimmune disease in the Genome
Wide Association Study Catalogue with a P-value ≤1×10-7
[29] (downloaded 13 June 2012). Samples were combined
into 25(OH)D ≥75 and 25(OH)D <75 by merging all bind-
ing sites from samples with 25-hydroxyvitamin D ≥75 nM
(n = 5) and <75 nM (n = 4). Overlap was determined
using segment-segment analysis with either 1,000 or
10,000 Monte-Carlo randomizations maintaining the em-
piric distribution of segment and inter-segment lengths,
but randomizing positions. Controlling for gene or im-
mune gene position (obtained from the Gene Ontology
project [30]) used an intensity track created based on the
proximity of (pooled) VDR regions to their nearest genes
or immune genes, respectively. VDR regions were repre-
sented as points (midpoints of VDR binding peaks) and a
point-segment analysis using 1,000 Monte-Carlo randomi-
zations with points sampled according to the intensity
track, were used to compute P-values (auto-immune
regions represented as segments as before). Immune
gene-controlled overlap omitted chromosome Y as no
immune genes were located there. Comparisons between
25(OH)D <75 and 25(OH)D ≥75 for overlap were per-
formed using case-control tracks generated by the
Genomic HyperBrowser and analyzed using valued seg-
ment–segment preferential overlap analysis with 10,000
Monte-Carlo randomizations, keeping the location of seg-
ments of both tracks constant, while randomly permuting
case-control values of the first track in the null model.
Heirarchical clustering analysis was performed in the
Genomic HyperBroswer by obtaining pairwise overlap-
enrichment values for each of the samples and computing
distance between samples as the inverse of these values.
Th1 DNase I hypersensitivity peaks were obtained from
the University of California at Santa Cruz (UCSC) Table
Browser and were generated by the Duke group [31].
ChIP-seq peaks for VDR in LCLs and MCLs were ob-
tained from previously published studies using VDR
binding intervals after stimulation with calcitriol [9,10],
and co-factor ChIP-seq peaks were obtained from the
Encyclopedia of DNA Elements (ENCODE) and Cistrome,
using ChIP-seq data from hematopoietic cell lines
(GM121878, K562 and NB4) [23,31-33]. ChIP-seq data
on chromatin states (H3K27Ac, H2A.Z, H3K4me1,
H3K4me2, H3K4me3, H3K9Ac and H3K9me3) in
GM12878 cells and chromatin looping 5C data were
obtained from ENCODE [34,35]. Gene expression data
from CD4+ cells was obtained from data published by
Birzele and colleagues [36]. Gene expression data from
LCLs in response to 1,25D3 treatment was obtained from
Ramagopalan and colleagues [9].
Results
VDR binding sites in CD4+ cells
VDR binding in samples from nine individuals ranged
from 200 to 7,118 binding sites across the genome.
There was a significant correlation between measured
25-hydroxyvitamin D levels and the number of VDR
binding sites (r = 0.92, P= 0.0005, Table 1).
For the purposes of analysis we split our samples into
two groups, one with sufficient 25-hydroxyvitamin D
(25(OH)D ≥75 nM, n = 5, 3 men, 2 women, age range
20 to 30 years, mean 25(OH)D 84.6 nM, range 75 to
107) and one with 25-hydroxyvitamin D insufficiency/
deficiency (25(OH)D <75 nM, n = 4, 2 men, 2 women,
age range 24 to 32 years, mean 29.3 nM, range 22 to 34;
25-hydroxyvitamin D in 25(OH)D ≥75versus 25(OH)D
<75P<0.05). Our cut-off of 75 nM is supported by
recommended clinical guidelines [37]. The five samples
with 25(OH)D ≥75 had many more VDR binding sites
than the four samples with 25(OH)D <75 (25(OH)D ≥75
mean number of binding sites 4,518 (range 3,059 to
7,118); 25(OH)D <75 mean number of binding sites 601
(range 200 to 1,021); 25(OH)D ≥75 versus 25(OH)D <75
P= 0.02). The genomic regions at which VDR bin-
ding sites were found also differed with vitamin D
level (Figure 1). This was predominantly driven by an
increase in intronic VDR binding in 25(OH)D ≥75 sam-
ples. For individual samples, VDR binding within 5 kb
downstream of genes (r = 0.82, P= 0.007) and within in-
trons (r = 0.79, P= 0.01) was correlated with vitamin D
levels, whereas VDR binding in areas with 5 kb upstream
(r = -0.14, P= 0.72) or both upstream and downstream
(r = 0.44, P= 0.24) of genes, within exons (r = -0.21,
P= 0.57), UTRs (r = -0.05, P= 0.89) or intergenic regions
(r = -0.40, P= 0.28) was not.
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We performed hierarchical clustering analysis using
pairwise overlap-enrichment of VDR binding sites and
this revealed far closer similarity between samples within
each group (25(OH)D ≥75 and 25(OH)D <75) than when
comparing samples between groups [see Additional file 2:
Figure S1]. Binding sites were also frequently shared bet-
ween samples, but 66.0% of binding sites were unique to a
single sample.
VDR binding and gene ontology
VDR binding sites were assessed for overlap with
known gene ontology biological pathways in GREAT
[See Additional file 3: Table S1] [26]. In 25(OH)D ≥75
samples, binding sites were maximally enriched for path-
ways involved in RNA processing, gene expression, pro-
tein folding and T cell activation or differentiation. In
contrast, the top pathways enriched for 25(OH)D <75
VDR binding were involved in RNA splicing, translation
and histone modification.
VDR binding motifs
We found that there was no significant enrichment of
binding sites containing DR3-like motifs either when
searching de novo using MEME-ChIP [20], CentriMo
[38], Weeder [21] or ChIPmunk [22] and analyzing all
binding sites, binding sites grouped by high or low
Table 1 Number of VDR binding sites
Sample/group 25-OH D Total Downstream Exons Intergenic Introns Up and
downstream
Upstream UTR
Number %
High 25-hydroxyvitamin D ≥75 13,054 5.3 4.0 32.8 28.4 4.7 14.6 10.2
Low 25-hydroxyvitamin D <75 1,526 3.7 4.8 36.5 18.6 4.3 18.8 13.3
1_VDR 80 3,073 5.2 3.9 37.9 24.0 4.7 13.8 10.5
2_VDR 107 7,118 5.6 4.5 28.2 26.3 5.1 17.0 13.2
3_VDR 76 5,290 5.4 3.5 36.8 29.1 4.1 12.9 8.3
4_VDR 85 3,059 5.1 4.0 37.3 22.3 4.7 15.6 11.0
5_VDR 75 4,051 4.6 4.8 33.0 21.5 5.3 18.8 12.1
HB 29 1,021 3.5 5.7 27.4 16.9 5.6 24.1 17.0
PD 32 200 1.0 3.0 61.7 21.4 0.5 7.0 5.5
SP 34 610 3.2 4.5 38.7 18.8 3.7 18.3 13.0
SR 22 573 3.5 4.9 39.7 17.7 4.0 18.5 11.7
r 0.92 0.82 −0.22 −0.40 0.79 0.44 −0.14 −0.05
P 0.0005 0.0068 0.5746 0.2822 0.0115 0.2401 0.7163 0.891
The number of VDR binding sites at FDR <0.1%. 25-hydroxyvitamin D (25(OH)D) levels are shown in nM. Correlations are shown between 25(OH)D and the
number of binding sites. VDR, vitamin D receptor.
Figure 1 Genomic regions of VDR binding sites. The midpoints of each VDR ChIP-seq peak is shown for (A) samples with 25-hydroxyvitamin
D ≥75 nM and (B) samples with 25-hydroxyvitamin D <75 nM. Up-, down- and up and downsteam are VDR binding sites within 5 kb of the
nearest gene. Numbers show percentages of binding sites within each genomic region. ChIP-seq, chromatin immunoprecipitation and massively
parallel sequencing; VDR, vitamin D receptor.
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vitamin D, binding sites overlapping with the previous
LCL or MCL VDR ChIP-seq studies, binding sites com-
mon between multiple samples or binding sites overlap-
ping with previous ChIP-seq studies of RXR in NB4 cells
[23]. Neither were DR3-like motifs found when each
sample was analyzed independently. The top consensus
binding sites are shown in Additional file 4: Figure S2
for each analysis approach. Our methods were, however,
able to detect the reported DR3 sites in previous VDR
ChIP-seq studies [9,10]. We were also unable to detect
VDR-like motifs when restricting our search to only
those parts of ChIP-seq intervals common to all samples
in the 25(OH)D ≥75 or 25(OH)D <75 groups.
As this was an unexpected finding, we performed an
in silico search within the pooled peaks but did not iden-
tify an over-representation of known VDR binding mo-
tifs using RSAT [24] and Fimo [25]. The existing RXRA::
VDR motif in the Jaspar [39] and TRANSFAC [40] data-
bases has been generated from SELEX data, which
mainly will represent strong binding without additional
co-factors or other context-dependent features. It is,
therefore, relevant to search for alternative variants of
VDR-like motifs that may be more representative of
in vivo binding. Since the CD4+ data set, in particular,
shows a lack of centrally enriched binding site motifs,
MEME-ChIP and CentriMo are less suitable for this.
Therefore, an iterative approach was used, in which the
full set of ChIP-Seq regions for LCL, MCL and the
merged set of CD4+ regions was searched with MAST
and the RXRA::VDR matrix (P-value 0.0001, E-value
100.0) [41]. The significant regions were submitted to
MEME for de novo motif discovery. In each data set a
VDR-like motif was found. This motif was used as input
to MAST again, and the resulting positive set was sub-
mitted to MEME, in order to reduce bias from the ori-
ginal RXRA::VDR motif. This process can, in principle,
be repeated several times, but in most cases the motifs
will start to degenerate after a while into very general
motifs with low information content. However, the
motifs generated in this case are clearly similar to the
classical RXRA::VDR motif, although with distinct differ-
ences [See Additional file 5: Figure S3]. They are also
similar to the previously published motifs for LCL and
MCL. These improved matrices were then used with
MAST to make positive and negative subsets for further
analysis. Here a slightly higher P-value was used (0.0005)
in order to include more borderline motifs, leading to
811 positive sequences (29%) for LCL, 648 (28%) for
MCL, and 90 (0.4%) for CD4+. This seems to confirm
the lack of VDR-like motifs in the CD4+ set. This was
further confirmed using FIMO to search each data set
with both the RXRA::VDR matrix and the individually
optimized matrices generated above [See Additional
file 6: Figure S4]. This showed a clear lack of significant
motifs in the CD4+ data, independent of which matrix
was used for searching. Analyzing CD4+ binding inter-
vals for other JASPAR motifs showed only a significant
overrepresentation of CTCF binding motifs in the 25
(OH)D ≥75 but not 25(OH)D <75 group.
We found significant overlap between CD4+ VDR and
RXR ChIP-seq peaks drawn from a promyelocytic cell
line (NB4; Additional file 7: Table S2) (25(OH)D ≥75
19.77-fold, P= 0.0004; 25(OH)D <75 65.14-fold, P<0.0001
[23]) and significant overlap between VDR binding sites in
CD4+ cells and those observed previously in LCLs
(25(OH)D ≥75 70-fold, P<0.0001; 25(OH)D <75 151.7-
fold, P<0.0001; 813/2,776 (29.3%) LCL VDR binding sites
overlap with VDR binding sites in CD4+ cells) and MCLs
(25(OH)D ≥75 28.75-fold, P<0.0001; 25(OH)D <75 37.17-
fold, P<0.0001; 353/1,818 (19.4%) MCL VDR binding sites
overlap with VDR binding sites in CD4+ cells) making it
likely that our data reflect real VDR binding sites.
Motifless binding has been described by the ENCODE
project with characteristically greater enrichment of
DNase I hypersensitivity than binding sites with classical
motifs [35]. We confirmed this in the previous LCL and
MCL VDR ChIP-seq datasets by dividing binding sites
into those with or without a VDR-like motif as detailed
above. Intervals containing the VDR-like motif had less
enrichment of DNase I peaks in GM12878 LCLs than
those intervals lacking that motif (LCL peaks with a
VDR-like motif (LCLmotif ), 24.6-fold, P<0.0001; LCL
peaks without a VDR-like motif (LCLno motif ), 27.8-fold,
P<0.0001; LCLmotif versus LCLno motif P= 0.0002;
MCLmotif, 13.5-fold, P<0.0001; MCLno motif, 18.0-fold,
P<0.0001; MCLmotif versus MCLno motif P= 0.0002). VDR
ChIP-seq peaks in the CD4+ cells in this study over-
lapped more with binding sites in LCLs and MCLs lack-
ing binding motifs than those with motifs (LCLmotif
37.4-fold, P<0.0001; LCLno motif 79.4-fold, P<0.0001;
LCLmotif versus LCLno motif P= 0.0002; MCLmotif, 17.7-
fold, P<0.0001; MCLno motif, 32.3-fold, P<0.0001;
MCLmotif versus MCLno motif P= 0.0002).
VDR co-factors, chromatin state and calcitriol-responsive
gene expression
We found significant overlap between the known VDR
co-factors SP1 in GM12878 cells (VD ≥75 45.86-fold,
P<0.0001; 25(OH)D <75 76.8-fold, P<0.0001), ETS1 in
GM12878 cells (25(OH)D ≥75 145.4-fold, P<0.0001; 25
(OH)D <75 373.5-fold, P<0.0001), NR4A1 in K562 cells
(25(OH)D ≥75 12.5-fold, P<0.0001; 25(OH)D <75 19.4-
fold, P<0.0001) and c-MYC in K562 cells (25(OH)D ≥75
83.9-fold, P<0.0001; 25(OH)D <75 155.4-fold, P<0.0001).
ChIP-seq data were from the UCSC Genome Browser
and our VDR binding sites [See Additional file 7: Table S2;
Figure 2] [31]. Given our finding that some VDR ChIP-
seq peaks were enriched for CTCF motifs, we analyzed
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overlap with known CTCF binding intervals in K562
cells and again found significant overlap (25(OH)D ≥75
22.26-fold, P<0.0001; 25(OH)D <75 17.16-fold, P<0.0001).
There was also significant overlap with open chromatin in
Th1 cells, as determined by DNase I hypersensitivity re-
gions (25(OH)D ≥75 18.93-fold, P<0.0001; 25(OH)D <75
23.71-fold, P<0.0001). For each of these analyses apart
from CTCF, 25(OH)D <75 was significantly more en-
riched for the tested genomic features than 25(OH)D ≥ 5
[See Additional file 7: Table S2].
VDR ChIP-seq peaks showed the highest enrichment
for chromatin marks in GM12878 cells associated with
transcriptional regulation (H3K27Ac, H2A.Z, H3K4me1,
H3K4me2, H3K4me3 and H3K9Ac) and far lower en-
richment for a repressive chromatin mark (H3K9me3)
[See Additional file 7: Table S2; Figure 3] [35].
There was significant enrichment of VDR binding
within 5 kb of genes responsive to 1,25D3 treatment
detected from microarray expression data in LCLs
(25(OH)D ≥75 3.86-fold, P<0.0001; 25(OH)D <75
Figure 2 Overlap of VDR ChIP-seq peaks with genomic features. 25(OH)D ≥75, samples with 25-hydroxyvitamin D ≥75 nM; 25(OH)D <75,
samples with 25-hydroxyvitamin D <75 nM; ChIP-seq, chromatin immunoprecipitation and massively parallel sequencing; LCL, lymphoblastoid cell
line; MCL, monocytic cell line; VDR, vitamin D receptor.
Figure 3 Overlap of VDR ChIP-seq peaks with chromatin marks. 25(OH)D ≥75, samples with 25-hydroxyvitamin D ≥75 nM; 25(OH)D <75,
samples with 25-hydroxyvitamin D <75 nM; ChIP-seq, chromatin immunoprecipitation and massively parallel sequencing; VDR, vitamin D receptor.
All bars shown are significant at P<0.0001.
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2.98-fold, P= 0.0002; 25(OH)D ≥75 versus 25(OH)D <75
P= 0.004) [9].
Given the relatively high proportion of intergenic VDR
binding sites, we tested for overlap with sites of known
chromatin looping in GM12878 cells in pilot ENCODE
regions [34]. There was significant but low magnitude
overlap of VDR binding and chromatin looping in 25
(OH)D ≥75 samples but not 25(OH)D <75 samples
(25(OH)D ≥75 1.07-fold, P= 0.002; 25(OH)D <75
0.73-fold, P= 0.83; 25(OH)D ≥75 versus 25(OH)D <75
P= 0.01).
VDR binding sites and autoimmune disease
We assessed overlap between VDR ChIP-seq peaks and
genomic regions encompassing the area 100 kb around
SNPs significantly associated with autoimmune disease
in genome wide association studies [29]. There was a
significant enrichment within all regions associated with
autoimmunity and this was greater for 25(OH)D ≥75
than 25(OH)D <75 (25(OH)D ≥75: 3.13-fold, P<0.0001;
25(OH)D <75: 2.76-fold, P<0.0001; 25(OH)D ≥75 en-
richment versus 25(OH)D <75 enrichment: P= 0.0002).
Overlap for individual autoimmune diseases is detailed
in Additional file 8: Table S3 and illustrated in Figure 4.
There was significant overlap for alopecia, ankylosing
spondylitis, celiac disease, Crohn’s disease, Grave’s dis-
ease, multiple sclerosis, primary biliary cirrhosis, psoria-
sis, psoriatic arthritis, rheumatoid arthritis, systemic
lupus erythematosus, systemic sclerosis, type 1 diabetes
mellitus, ulcerative colitis and vitiligo. In most condi-
tions, there was more overlap for 25(OH)D ≥75 than 25
(OH)D <75. One possible explanation would be that
both VDR binding and autoimmune disease regions tend
to cluster near regions enriched for genes so the analysis
was repeated controlling for the location of genes and
immune-related genes. Controlling for immune-related
genes reduced the significance for some autoimmune
diseases (notably rheumatoid arthritis) suggesting that
VDR binding near immune-genes may underlie some of
the enrichment seen near autoimmune disease regions.
However, overall overlap with autoimmune disease re-
gions was still significant suggesting that VDR enrich-
ment of these regions is at least partially independent of
preferential binding near immune-related genes. We
Figure 4 Overlap of VDR ChIP-seq peaks with autoimmune disease-associated regions. Autoimmune disease associated regions are those
within 100 kb of SNPs implicated in genome-wide association studies (GWAS) at P<10-7 [29]. 25(OH)D ≥75,samples with 25-hydroxyvitamin
D ≥75 nM, 25(OH)D <75, samples with 25-hydroxyvitamin D <75 nM; ChIP, ChIP-seq, chromatin immunoprecipitation and massively parallel
sequencing; VDR, vitamin D receptor.
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assessed enrichment for autoimmune disease-associated
regions in all VDR binding sites overlapping with ChIP-
seq peaks for other transcription factors and found the
greatest enrichment for overlap with SP1 and CTCF but
comparisons between VDR binding sites overlapping
with transcription factor ChIP-seq peaks and those with-
out overlap were not significant [See Additional file 9:
Table S5].
There was no significant enrichment for genomic re-
gions associated with control conditions (ones in which
CD4+ cells would not be expected to play a dominant
role), such as coronary heart disease, atopic dermatitis
and type 2 diabetes mellitus (P>0.05 for all). Also, in
support of separate biochemical pathways for auto-
immunity and metabolic effects of vitamin D, VDR bind-
ing was not enriched for genomic regions associated
with bone mineral density.
The previous study of LCLs had shown VDR enrich-
ment near regions associated with chronic lymphocytic
leukemia. However, no significant enrichment was seen
for these regions in primary CD4+ cells (25(OH)D ≥75
1.62-fold, P= 0.37; 25(OH)D <75 2.44-fold, P= 0.27;
LCLs 20.7-fold, P<0.0001), suggesting that VDR binding
in cell lines differs considerably from that seen in pri-
mary immune cells.
Although 100 kb was chosen to encompass the likely
extent of linkage disequilibrium,both groups showed in-
creased enrichment when the size of the region assessed
for overlap decreased. 25(OH)D ≥75 showed consistently
greater enrichment for autoimmune regions than 25
(OH)D <75 [See Additional file 10: Figure S5].
Several disease-associated SNPs were located within
VDR ChIP-seq binding intervals [See Additional file 11:
Table S4]. We analyzed these SNPs in Regulome DB and
found that several were likely to affect gene expression
and/or transcription factor binding [42].
VDR binding and gene expression in CD4+ cells
We assessed enrichment in VDR binding near genes
expressed in different types of CD4+ cells measured by
RNA-seq [36]. VDR binding was significantly enriched
within 5 kb of genes expressed either specifically in
T-regulatory cells or T-helper cells and genes expressed
which were common to all CD4+ cells. Enrichment was
particularly high for genes associated specifically with T-
regulatory and T-helper cells in the 25(OH)D ≥75 group
(RNA-seq Treg: 25(OH)D ≥75 4.07-fold, P<0.0001; 25
(OH)D <75 2.96-fold, P<0.0001; 25(OH)D ≥75 versus 25
(OH)D <75 P= 0.0002; RNA-seq Thelper: 25(OH)D ≥75
3.87-fold, P<0.0001; 25(OH)D <75 2.76-fold, P<0.0001;
25(OH)D ≥75 versus 25(OH)D <75 P= 0.0002; RNA-seq
CD4 + common: 25(OH)D ≥75 5.27-fold, P<0.0001; 25
(OH)D <75 5.13-fold, P<0.0001; 25(OH)D ≥75 versus 25
(OH)D <75 P= 0.0002).
Discussion
The most arresting finding in this study is that the num-
ber of VDR binding sites in primary CD4+ cells is
strongly correlated with 25-hydroxyvitamin D levels.
The previous VDR ChIP-seq experiments using MCLs
and LCLs found an increase in VDR binding site occu-
pancy following treatment with supraphysiological levels
of calcitriol [9,10]. Our finding of a far greater number
of VDR binding sites in sufficient vitamin D samples
than insufficient samples suggests that this effect also
occurs with different in vivo levels of vitamin D. In vivo
levels of 25-hydroxyvitamin D are directly associated
with the number of VDR binding sites.
VDR binding sites are enriched for markers of active
transcription and open chromatin; 25(OH)D ≥75 sam-
ples seemed to be less enriched for these markers than
25(OH)D <75, perhaps reflecting binding to open chro-
matin state in 25(OH)D <75 samples.
We have confirmed that the observation of significant
overlap between VDR binding and genomic regions
implicated in autoimmune diseases in LCLs is also seen
in primary CD4+ cells [9,10]. Gene ontology analysis
suggests that VDR binding in conditions of 25-hydro-
xyvitamin D sufficiency may be more directly related to
immune cell function. This is supported by the observed
higher levels of VDR binding near genes expressed specif-
ically in T-regulatory and T-helper cells in 25(OH)D ≥75
but not 25(OH)D <75 samples.
We found a lack of classical VDR binding motifs
within the VDR ChIP-seq peaks. In the ChIP-seq studies
in MCLs and LCLs the authors identified classical DR3
motifs at differing proportions of sites (32% in MCLs,
67% in LCLs) with SP1-like and ETS-like non-classical
peaks identified in the MCL ChIP-seq study (23% and
12% respectively) [9,10]. We found enrichment of CTCF
motifs in several of our samples but were unable to
identify any previously described VDR motifs. One pos-
sibility is that in vivo VDR binding is modulated by
protein-protein interactions with co-factors: SP1 and
ETS1 are known to modulate VDR binding, and there is
some evidence that interactions between SP1 and VDR
may enable modulation of genes that lack a classical
VDR recognition motif [43,44]. Several other proteins
are known to bind in association with VDR, including
NR4A1 and c-MYC [45,46]. CTCF is known to modulate
DNA binding via protein-protein interactions with other
nuclear receptors [47-49]. However, it is unlikely that
protein-protein interactions with transcription factors
with specific recognition sequences can explain most
of these motifless binding sites since one would have
expected to find that motif through MEME-ChIP ana-
lysis. It may be that in response to physiological levels
of 25-hydroxyvitamin D most VDR binding occurs
at motifless binding sites similar to those identified by
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ENCODE [35], supported by the increased overlap with
DNase I peaks. Another possibility is that the lack of
motifs may reflect the fact that these CD4+ cells were
not stimulated with 1,25D3, as the previous LCL ChIP-
seq did not find classical motifs prior to stimulation [9].
Alternatively, current motif-finding methods may be in-
sufficient to locate true VDR binding motifs. Further re-
search will be needed in more lymphocyte subsets to
delineate further the role of non-classical binding sites
in VDR binding. It would also be useful to obtain 1,25D3,
parathyroid hormone and calcium measurements for fu-
ture study.
The overlap between genomic regions associated with
many autoimmune diseases and VDR binding in primary
CD4+ cells strongly suggests a role for vitamin D in
many of these diseases, as already seen for MCLs and
LCLs [9,10]. This is strengthened by the observation that
this effect tends to be stronger in individuals sufficient
for 25-hydroxyvitamin D. Interestingly, the magnitude of
enrichment for autoimmunity increased as the flanks of
the region surrounding implicated SNPs was reduced.
This further suggests that this is not a chance finding
and that VDR binding may have a functional role in
modulating adaptive immunity in autoimmune diseases.
We also controlled for genomic architectural features
that could bias our results and observed that the results
were not substantively altered. Future functional work
should focus on the effects of VDR binding on nearby
gene expression and targeted sequencing in patients with
autoimmune conditions to identify possible rare variants
affecting VDR binding.
Conclusions
The role of vitamin D in bone health has long been
established. The involvement of this vitamin in auto-
immune disease is however heavily debated. We provide
here an in vivo mechanism as to how vitamin D defi-
ciency may influence autoimmune disease risk, by dir-
ectly interacting with disease associated genes. Vitamin
D sufficiency has been suggested to have a threshold of
approximately 75 nmol/L; we provide here biological
evidence in support of this, with significant public health
implications.
Consent
All subjects gave written informed consent for their
samples to be used in this study.
Additional files
Additional file 1: Supplementary dataset. VDR binding sites in
samples with high and low 25-hydroxyvitamin D. Genomic co-ordinates
are shown in hg19. 25(OH)D≥75 = samples with 25-hydroxyvitamin D
≥75 nM, 25(OH)D<75 = samples with 25-hydroxyvitamin D <75 nM.
Additional file 2: Figure S1. Heirarchical clustering of VDR ChIP-seq
peaks for individual samples. (A) Distance matrix computing distances as
the inverse of overlap-enrichment pairwise similarity between samples
(color scheme ranges from red for most similar to white for least similar).
(B) Dendrogram incorporating the distances from the distance matrix.
V1-5, VDR_1 to VDR_5; 25-hydroxyvitamin D ≥75 nM. HB, PD, SP and SR,
25-hydroxyvitamin D <75 nM.
Additional file 3: Table S1. Top gene ontology terms by binomial
FDR Q-value. Values are derived from GREAT. 25(OH)D≥75 = subjects
with vitamin D levels ≥75 nM, 25(OH)D<75 = subjects with vitamin D
levels <75 nM.
Additional file 4: Figure S2. Top MEME-ChIP motifs for VDR ChIP-seq
peaks. This figure shows the top two motifs for each set of VDR ChIP-seq
peaks by E-score as established by MEME-ChIP [15]: VD ≥ 75, samples
with 25-hydroxyvitamin D ≥75 nM; VD <75, samples with 25-
hydroxyvitamin D <75 nM. CD4+ VDR ChIP-seq peaks overlapping LCL VDR
ChIP-seq peaks and CD4+ VDR ChIP-seq peaks overlapping NB4 RXR ChIP-
seq peaks.
Additional file 5: Figure S3. Sequence logos for VDR-like binding site
motifs. The motifs were identified for each data set by searching the full
ChIP-Seq regions with the Jaspar/TRANSFAC RXRA::VDR motif using
MAST, followed by de novo motif discovery with MEME on the positive
regions from MAST [15]. The resulting VDR-like matrix was used for
another round of MAST searching on the full ChIP-Seq regions and
MEME motif discovery on the positive set. The final matrices are shown
for (A) LCL (434 sites used by MEME), (B) MCL (288 sites), (C) CD4+
(56 sites), and (D) Jaspar/TRANSFAC RXRA::VDR. The observation that the
LCL and MCL logos are more similar to each other than to the RXRA::VDR
logo, whereas the logo for CD4+ is more similar to the RXRA::VDR logo,
may reflect the fact that the two first logos are based on a much larger
number of sites and are, therefore, more likely to represent the true
binding site motif for strong binding.
Additional file 6: Figure S4. Number of sequences retrieved from each
data set by motif-based searches. Motif occurrences were identified using
FIMO with (A) the RXRA::VDR motif, or (B) individually optimal matrices
for each data set (LCL, MCL and CD4+) [20]. The number of sequences
with at least one motif is plotted as a function of motif P-value. Each
P-value is corrected for data set size by multiplying it with the number
of tests.
Additional file 7: Table S2. Enrichment of genomic features within
VDR binding sites. This shows the enrichment within VDR binding
intervals for VDR binding intervals in lymphoblastoid cell lines (LCL VDR)
and monocytic cell lines (MCL VDR), and other genomic features drawn
from Cistrome and ENCODE [18,25,44]. 25(OH)D≥75 = subjects with
vitamin D levels ≥75 nM, 25(OH)D<75 = subjects with vitamin D
levels <75 nM, O/E = observed/expected overlap of genomic intervals,
p = p-value calculated from 10,000 Monte-Carlo randomisations.
Additional file 8: Table S3. Enrichment of autoimmune disease
susceptibility regions within VDR binding sites. Autoimmune susceptibility
regions were defined as those within 100kb of SNPs associated with
autoimmune disease [27]. 25(OH)D≥75 = subjects with vitamin D
levels ≥75 nM, 25(OH)D<75 = subjects with vitamin D levels <75 nM,
O/E = observed/expected overlap of genomic intervals, p = p-value
calculated from 10,000 Monte-Carlo randomisations, p(genes) = p-value
controlling for position of genes calculated from 1,000 Monte-Carlo
randomisations, p(immune genes) = p-value controlling for position of
immune-related genes calculated from 1,000 Monte-Carlo
randomisations. P(genes) and p(immune genes) are calculated only for
enrichment with uncontrolled p<0.05.
Additional file 9: Table S5. Enrichment of autoimmune disease
associated regions with and without other transcription factors present at
each VDR binding site. O/E, = observed/expected overlap of genomic
intervals; P, = P-value calculated from 10,000 Monte-Carlo randomizations.
Additional file 10: Figure S5. Overlap with autoimmune disease
association regions with variable distances around autoimmune single
nucleotide polymorphisms. Enrichment is shown for different distances in
base-pairs around SNPs from genome-wide association studies (GWAS)
implicated in autoimmune diseases with P<10-7 [27].
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Additional file 11: Table S4. Autoimmune disease-associated single
nucleotide polymorphisms located within VDR ChIP-seq peaks.
RegulomeDB score: 1a eQTL + TF binding + matched TF motif +
matched DNase Footprint + DNase peak; 1b eQTL + TF binding + any
motif + DNase Footprint + DNase peak; 1c eQTL + TF binding +
matched TF motif + DNase peak; 1d eQTL + TF binding + any motif +
DNase peak; 1e eQTL + TF binding + matched TF motif; 1f eQTL + TF
binding/DNase peak; 2a TF binding + matched TF motif + matched
DNase Footprint + DNase peak; 2b TF binding + any motif + DNase
Footprint + DNase peak; 2c TF binding + matched TF motif + DNase
peak; 3a TF binding + any motif + DNase peak; 3b TF binding + matched
TF motif; 4 TF binding + DNase peak; 5 TF binding or DNase peak;
6 other; 7 no functional annotation.25(OH)D≥75 = samples with
25-hydroxyvitamin D ≥75 nM, 25(OH)D<75 = samples with
25-hydroxyvitamin D <75 nM, TF = transcription factor.
Abbreviations
1,25D3: 1,25-dihydroxyvitamin D; 25-OH D: 25-hydroxyvitamin D;
ChIP-seq: Chromatin immunoprecipitation and massively parallel sequencing;
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25-hydroxyvitamin D <75 nM.
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